NEW YORK (GenomeWeb News) – Sequenom announced after the close of the market on Thursday that revenues spiked 38 percent year over year during the second quarter as the MaterniT21 Plus fetal aneuploidy test continued to see strong adoption.

For the period ended June 30, total revenues came in at $18.3 million, compared to $13.3 million a year ago, but missed the consensus analyst estimate of $19.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.